FindTrial
Sign In

IRINOTECAN HYDROCHLORIDE TRIHYDRATE

DRUG7 trials

Sponsors

Hopital Erasme, Centre Hospitalier Universitaire De Dijon, Region Skane, Charite Universitaetsmedizin Berlin KöR, AstraZeneca AB

Conditions

Esophageal CancerPancreatic adenocarcinomaResectabel gastric and gastroesophageal junction adenocarcinomaSmall bowel adenocarcinomaUnresectable or Metastatic Colorectal CancerUntreatedmetastatic colorectal cancer​​Colorectal cancer​

Phase 2

Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer
CompletedNCT00160875
University Health Network, TorontoEsophageal Cancer
Start: 2009-04-30End: 2011-03-31Updated: 2017-05-04
Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma: a randomised comparative multicentre phase II study (STEREOPAC)
RecruitingCTIS2022-501181-22-01
Hopital ErasmePancreatic adenocarcinoma
Start: 2023-02-06Target: 256Updated: 2024-01-10
PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
RecruitingCTIS2023-505486-92-00
Centre Hospitalier Universitaire De DijonSmall bowel adenocarcinoma
Start: 2024-02-09Target: 170Updated: 2025-11-27
Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma.
Active, not recruitingCTIS2023-509044-96-00
Region SkaneResectabel gastric and gastroesophageal junction adenocarcinoma
Start: 2018-12-21Target: 57Updated: 2024-05-22
​​A Phase II, Open-Label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer (CANTOR)
RecruitingCTIS2024-518469-84-00
AstraZeneca AB​​Colorectal cancer​
Start: 2025-06-20Target: 69Updated: 2025-06-13
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Not yet recruitingCTIS2025-523224-45-00
Bristol-Myers Squibb Services Unlimited CompanyUnresectable or Metastatic Colorectal Cancer, Untreated
Target: 33Updated: 2026-03-11

Phase 3

Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ ablation therapy in patients with metastatic colorectal cancer.
RecruitingCTIS2024-512174-10-00
Charite Universitaetsmedizin Berlin KöRmetastatic colorectal cancer
Start: 2021-11-11Target: 507Updated: 2025-09-04

Related Papers

Abstract A001: Preoperative treatment with mFOLFIRINOX +/- isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): A randomized comparative multicenter phase II trial
Cancer Research2024-01-16
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
2023-09-217 citations